GlassScriptPhysician profile
Victoria Rizk
NPI 1518200195
$257,607.18
in general payments reported to CMS, 2019-2025
25 companies · $103K in 2025
The $103K reported for 2025 was more than what 99% of Hematology & Oncology providers received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $528 · 2022: $785 · 2023: $58K · 2024: $95K · 2025: $103K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $195K · Consulting Fee: $27K · Travel and Lodging: $23K · Food and Beverage: $8,269 · Long Term Medical Supply Or Device Loan: $2,299 · Education: $135.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $195,210.00 |
| Consulting Fee | $27,250.00 |
| Travel and Lodging | $23,131.15 |
| Food and Beverage | $8,269.13 |
| Long Term Medical Supply Or Device Loan | $2,299.02 |
| Education | $134.84 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Gilead Sciences, INC. | $190,355.73 | 2022-2025 | Trodelvy |
| Lilly USA, LLC | $40,202.62 | 2022-2025 | Verzenio, Jaypirca, Retevmo |
| Springworks Therapeutics, INC. | $10,009.17 | 2024-2025 | Ogsiveo, Gomekli |
| Novartis Pharmaceuticals Corporation | $6,718.23 | 2019-2025 | Kisqali |
| Deciphera Pharmaceuticals INC. | $4,442.32 | 2023-2024 | Qinlock |
| Daiichi Sankyo INC. | $2,224.85 | 2022-2025 | Enhertu, Datroway |
| Astrazeneca Pharmaceuticals LP | $1,743.44 | 2023-2025 | Enhertu |
| Genentech USA, INC. | $362.20 | 2019-2024 | Phesgo, Perjeta, Itovebi |
| Aadi Bioscience, INC. | $289.59 | 2023-2024 | Fyarro |
| Pfizer INC. | $213.96 | 2019-2025 | |
| Eisai INC. | $188.52 | 2023 | |
| Seagen INC. | $165.13 | 2023-2025 | Adcetris |
| Servier Pharmaceuticals LLC | $125.00 | 2023 | |
| Jazz Pharmaceuticals INC. | $107.53 | 2025 | |
| Genentech, INC. | $100.38 | 2022 |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Beone Medicines USA, INC. | $94.57 | 2025 | Brukinsa |
| Tersera Therapeutics LLC | $90.53 | 2025 | Zoladex |
| Boehringer Ingelheim Pharmaceuticals, INC. | $33.26 | 2023 | Gilotrif |
| Stemline Therapeutics INC. | $29.12 | 2023 | Orserdu |
| Genzyme Corporation | $25.85 | 2025 | |
| Astellas Pharma US INC | $24.97 | 2024 | Cresemba |
| Alexion Pharmaceuticals, INC. | $21.85 | 2025 | Ultomiris |
| Genmab U.S., INC. | $20.42 | 2023 | Epkinly |
| Tempus Ai, INC | $17.94 | 2025 | Xt Cdx |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Victoria Rizk listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.